Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CLK2 | P49760 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TOP1 | P11387 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3197064 | 1.00 | KCNH2 (0.54) | KCNH2KDM4EALDH1A1HPGDPOLB | |
| Hydrochloric Acid SCHEMBL5527915 | 0.99 | KCNH2 (0.53) | KCNH2KDM4EALDH1A1HPGDPOLB | |
| Hydrochloric Acid SCHEMBL5439095 | 0.98 | KCNH2 (0.53) | KCNH2KDM4EALDH1A1HPGDPOLB | |
| SCHEMBL6504574 | 0.90 | KCNH2 (0.67) | KCNH2KDM4EALDH1A1HPGDPOLB | |
| SCHEMBL12961917 | 0.90 | KCNH2 (0.53) | KCNH2KDM4EALDH1A1HPGDPOLB | |
| SCHEMBL14377772 | 0.88 | KCNH2 (0.40) | KCNH2KDM4EALDH1A1HPGDPOLB | |
| Sitafloxacin Anhydrous SCHEMBL74553 | 0.87 | ALDH1A1 (0.59) | KCNH2KDM4EALDH1A1HPGDPOLB | |
| Sitafloxacin Anhydrous SCHEMBL21416358 | 0.87 | ALDH1A1 (0.59) | KCNH2KDM4EALDH1A1HPGDPOLB | |
| Sitafloxacin Anhydrous SCHEMBL13483604 | 0.87 | ALDH1A1 (0.59) | KCNH2KDM4EALDH1A1HPGDPOLB | |
| Sitafloxacin Anhydrous SCHEMBL1652843 | 0.87 | ALDH1A1 (0.59) | KCNH2KDM4EALDH1A1HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558349-B2 | Methods of treating infections in overweight and obese patients using antibiotics | MELINTA SUBSIDIARY CORP. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12036219-B2 | Methods of treating infections in overweight and obese patients using antibiotics | MELINTA SUBSIDIARY CORP. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240165100-A1 | METHODS OF TREATING INFECTIONS IN OVERWEIGHT AND OBESE PATIENTS USING ANTIBIOTICS | MELINTA SUBSIDIARY CORP. | 2024-05-23 | — | — | US | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| CN-117597327-A | Pharmaceutical preparation | 第一波动生物制药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11564896-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20220257584-A1 | METHODS OF TREATING INFECTIONS IN OVERWEIGHT AND OBESE PATIENTS USING ANTIBIOTICS | MELINTA SUBSIDIARY CORP. | 2022-08-18 | — | — | US | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220257584-A1 | METHODS OF TREATING INFECTIONS IN OVERWEIGHT AND OBESE PATIENTS USING ANTIBIOTICS | CLPP, MGAM, MMP8 | KCNH2 4561/4885KDM4E 3942/4885ALDH1A1 2778/4885 |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | KCNH2 1025/4885KDM4E 2452/4885ALDH1A1 2174/4885 |
| US-12036219-B2 | Methods of treating infections in overweight and obese patients using antibiotics | NCEH1, NRDC, LPL | KCNH2 4200/4885KDM4E 3706/4885ALDH1A1 1703/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | KCNH2 1715/4885KDM4E 3249/4885ALDH1A1 3977/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | KCNH2 1715/4885KDM4E 3249/4885ALDH1A1 3977/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | KCNH2 1699/4885KDM4E 3157/4885ALDH1A1 3889/4885 |
| US-20240165100-A1 | METHODS OF TREATING INFECTIONS IN OVERWEIGHT AND OBESE PATIENTS USING ANTIBIOTICS | CLPP, MGAM, MMP8 | KCNH2 4561/4885KDM4E 3942/4885ALDH1A1 2778/4885 |
| US-11564896-B2 | Methods of treatment | ACE2, ACE, SI | KCNH2 1699/4885KDM4E 3157/4885ALDH1A1 3889/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | KCNH2 1699/4885KDM4E 3157/4885ALDH1A1 3889/4885 |
| US-12558349-B2 | Methods of treating infections in overweight and obese patients using antibiotics | CUTA, PADI4, FABP4 | KCNH2 1684/4885KDM4E 1895/4885ALDH1A1 2750/4885 |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FH, IDH2, ECHS1 | KCNH2 726/4885KDM4E 2021/4885ALDH1A1 2305/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | KCNH2 1112/4885KDM4E 2466/4885ALDH1A1 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.